Navigation Links
GranuFlo Lawsuits Moving Forward in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports
Date:7/10/2013

New York, New York (PRWEB) July 10, 2013

GranuFlo lawsuit claims filed in the wake of Fresenius Medical Care’s GranuFlo and NaturaLyte dialysis drug recall have begun to move forward in a federal multidistrict litigation underway in the U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP reports. Court records indicate that more than 300 Fresenius Granuflo lawsuits are now pending in the multidistrict litigation. On June 21st, a motion was filed with the Court asking U.S. District Judge Douglas P. Woodlock to schedule the proceeding’s Initial Case Management Conference, and to name plaintiffs’ attorneys to leadership positions in the litigation. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“We are not surprised that the number of GranuFlo lawsuits filed in this litigation have surpassed 300. Our Firm continues to hear from patients affected by the GranuFlo and NaturaLyte recall who have experienced catastrophic heart problems, allegedly due to the administration of these drugs,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to dialysis patients who suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other side effects allegedly related to the GranuFlo and NaturaLyte recall.

GranuFlo and NaturaLyte Recall
All of the Fresenius GranuFlo lawsuits pending in the District of Massachusetts allege Fresenius Medical Care was aware of the heart risks associated with GranuFlo and NaturaLyte, but failed to provide adequate warnings regarding those risks. Both GranuFlo and Naturalyte were the subject of an “Urgent Product Notification” Fresenius issued to its customer clinics in March of 2012 that warned of possible heart risks associated with the products. The U.S. Food & Drug Administration (FDA) later deemed the notification a Class I recall, its most serious class of safety alert. According to the FDA, dialysis patients treated with GranuFlo and NaturaLyte may experience elevated levels of bicarbonate in the blood, which can lead to catastrophic heart side effects, including cardiopulmonary arrest and sudden cardiac death.*

According to a New York Times report published in June 2012, Fresenius Medical Care treats more than a third of the estimated 400,000 Americans receiving dialysis and is the leading supplier of dialysis machines and disposable products. The FDA launched an investigation into the timing of the GranuFlo and NaturaLyte recall, after learning that Fresenius had issued a memo in November 2011 to its own clinics that warned of the heart risks associated with the drugs, and advised doctors to adjust their dosage to avoid these dangers. A similar warning was not issued by the company to its customer clinics at that time, the Times reported.**

Dialysis patients who suffered heart attacks, sudden cardiac death, and other catastrophic heart side effects within 48 hours of a dialysis treatment with GranuFlo and NaturaLyte may be entitled to compensation for their injuries. To learn more about filing a Fresenius GranuFlo lawsuit, please visit Bernstein Liebhard LLP’s website. For additional information, and to arrange for a free legal consultation, please call 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

*fda.gov/MedicalDevices/Safety/ListofRecalls/ucm309990.htm; FDA, March 29, 2013
**nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html;

New York Times, June 14, 2012
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.granuflodialysislawsuits.com/

Read the full story at http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb10917610.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama
2. GranuFlo Lawsuit News: Bernstein Liebhard LLP Reports on Growing Litigation Surrounding GranuFlo Recall
3. New Granuflo Cardiac Arrest Lawsuit: Now, AttorneyOne Can Provide Advice
4. The National Plaintiff’s Law Firm of Baron and Budd Handling Granuflo Recall Lawsuits
5. GranuFlo Lawsuits Filed in Wake of GranuFlo and NaturaLyte Recall Mount in State and Federal Courts, Bernstein Liebhard LLP Reports
6. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
7. GranuFlo Recall Website Launched By Hissey Kientz, LLP Law Firm
8. GranuFlo Lawsuit Consolidation Supported by Fresenius Medical Care, Bernstein Liebhard LLP Reports
9. Federal Byetta, Victoza, Januvia Lawsuits Could See Consolidation This Month, Rottenstein Law Group LLP Reports
10. DePuy ASR Lawsuits Progressing, Notes Rottenstein Law Group LLP
11. Mirena IUD Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Case Management Conference in Federal Mirena Side Effects Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Newark, NJ (PRWEB) , ... April 28, 2017 , ... ... Poor’s has affirmed the company’s credit rating of “A” and its outlook as “stable.” ... downgraded if capital reserves, which have fallen in recent years, dip below “capital adequacy” ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today a ... the Northeast U.S. , GlycoMark is the only clinically available blood test ... a clinically proven one- to two-week measure of hyperglycemic excursions, often related to ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... Replace tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent ... rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... that Aditya Patel M.D. has joined the revolutionary endoscopic practice under Dr. Datta. ... certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used ...
(Date:4/28/2017)... ... , ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical ... Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord ... donate. , “Women’s Hospital at Renaissance has been a collection partner for the ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... CITY, Calif. , April 24, 2017 ... durability, grip, protection, and comfort, announces the release of ... Powerform S8+. This most recent example of leading edge ... density grip pattern for 200% more tactile grip on ... user protection and durability. With TracTek and a suite ...
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
Breaking Medicine Technology: